Results 61 to 70 of about 77,108 (288)

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis

Advanced Science, EarlyView.
This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.
Sarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, Alina Krumme, Maxime Le Marois, Angelika Fraas, Aslihan Inal, Mario Huerta, Vanessa Henriques, Eva Eiteneuer, Thomas Albrecht, Alphonse Charbel, Michael T. Dill, Carsten Sticht, Carolina De La Torre, Stefan Pusch, Arianeb Mehrabi, Kai Breuhahn, Junfang Ji, Peter Schirmacher, Benjamin Goeppert, Stephanie Roessler   +21 more
wiley   +1 more source

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study

Frontiers in Oncology, 2020
Background: The development of biomarkers predictive of response to immune checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest in oncology.
Muhammad A. Khattak, Muhammad A. Khattak, Muhammad A. Khattak, Afaf Abed, Afaf Abed, Anna L. Reid, Ashleigh C. McEvoy, Michael Millward, Michael Millward, Melanie Ziman, Elin S. Gray   +10 more
doaj   +1 more source

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]

, 2020
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al, Blanke, Charles D, Chae, Young Kwang, Chen, Helen X, Fontaine, Annette, Gatalica, Zoran, Giles, Francis J, Hansel, Donna E, Hayward, Jourdain, Kasi, Anup, Korn, W Michael, Kurzrock, Razelle, Matrana, Marc, Mayerson, Edward, McLeod, Christine, Othus, Megan, Patel, Sandip P, Plets, Melissa, Ryan, Christopher W, Shah, Manisha H, Sharon, Elad, Singh, Preet Paul   +21 more
core  

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program [PDF]

, 2019
Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.
Buti, S, Cappuzzo, F, Cartenì, G, Cognetti, F, Cortesi, E, De Giglio, A, De Giorgi, U, Giannarelli, D, Panni, S, Pazzola, A, Porta, C, Procopio, G, Raimondi, A, Rastelli, F, Rossetti, S, Sabbatini, R, Sobrero, A, Sternberg, Cn, Surico, G, Tassinari, D, Tortora, G, Turci, D, Verzoni, E   +22 more
core   +3 more sources

Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]

, 2020
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia, Consoli, Francesca, Monti, Matilde, Vermi, William, Vescovi, Raffaella   +4 more
core   +2 more sources

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Journal for ImmunoTherapy of Cancer, 2022
Background CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features ...
S. Tykodi, L. Gordan, R. Alter, E. Arrowsmith, M. Harrison, I. Percent, R. Singal, P. V. Van Veldhuizen, D. George, T. Hutson, Joshua Zhang, Jesús Zoco, J. Johansen, Arash Rezazadeh Kalebasty   +13 more
semanticscholar   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review

Melanoma Management, 2018
Introduction: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma.
Elizabeth S Mearns, Jill A Bell, Aaron Galaznik, Stefanie M Puglielli, Allie B Cichewicz, Talia Boulanger, Ignacio Garcia-Ribas   +6 more
doaj   +1 more source

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth, Koyfman, Alex, Long, Brit Jeffrey   +2 more
core  

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]

, 2018
In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A., Marchetti, P., Nuti, M., Rughetti, A., Zizzari, I. G.   +4 more
core   +1 more source